ERBB2 and breast cancer: The immunostaining results for HER2‐negative human breast cancer tissue samples with anti‐PAR1 antibody‐conjugated QDs showed that the PAR1 expression level in cancer cells with a poor prognosis was strongly correlated with the prognosis of HER2‐negative breast cancer patients.